GR1001145B - Μεθοδος για την αντιμετωπιση αγγειακων ασθενειων. - Google Patents

Μεθοδος για την αντιμετωπιση αγγειακων ασθενειων.

Info

Publication number
GR1001145B
GR1001145B GR890100773A GR890100773A GR1001145B GR 1001145 B GR1001145 B GR 1001145B GR 890100773 A GR890100773 A GR 890100773A GR 890100773 A GR890100773 A GR 890100773A GR 1001145 B GR1001145 B GR 1001145B
Authority
GR
Greece
Prior art keywords
vascular diseases
facing
diabetic nephropathy
diabetic
renin
Prior art date
Application number
GR890100773A
Other languages
English (en)
Other versions
GR890100773A (en
Inventor
D Kleinert Hollis
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of GR890100773A publication Critical patent/GR890100773A/el
Publication of GR1001145B publication Critical patent/GR1001145B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στη χρήση αναστολέων ρενίνης και σε συνθέσεις αναστολέων ρενίνης για την αγωγή, αναστολή, ανακούφιση ή ανατροπή των αγγειακών ασθενειών που περιλαμβάνουν εκείνες τις αγγειακές ασθένειες που συνδεόνται με λειτουργικές και/ή βιοχημικές ανωμαλίες, και ειδικά περιφερικές αγγειακές ασθένειες και μικροαγγειακές ασθένειες που συνδέονται με τον διαβήτη, ειδικά διαβητική αμφιβληστροειδοπάθεια, διαβητική νεφροπάθεια και διαβητική νεφροπάθεια. ω
GR890100773A 1988-11-21 1989-11-21 Μεθοδος για την αντιμετωπιση αγγειακων ασθενειων. GR1001145B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27515188A 1988-11-21 1988-11-21

Publications (2)

Publication Number Publication Date
GR890100773A GR890100773A (en) 1990-12-31
GR1001145B true GR1001145B (el) 1993-05-24

Family

ID=23051068

Family Applications (1)

Application Number Title Priority Date Filing Date
GR890100773A GR1001145B (el) 1988-11-21 1989-11-21 Μεθοδος για την αντιμετωπιση αγγειακων ασθενειων.

Country Status (4)

Country Link
EP (1) EP0444156A4 (el)
CA (1) CA2003382A1 (el)
GR (1) GR1001145B (el)
WO (1) WO1990005531A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
US5244910A (en) * 1990-08-15 1993-09-14 Abbott Laboratories Renin inhibitors
ZA921381B (en) * 1991-03-01 1992-11-25 Fujisawa Pharmaceutical Co New use of amino acid derivatives
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DE60022525T2 (de) * 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
EP1358178A2 (en) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3418491A1 (de) * 1984-05-18 1985-11-21 Merck Patent Gmbh, 6100 Darmstadt Diaminosaeurederivate
DE3438545A1 (de) * 1984-10-20 1986-04-24 Merck Patent Gmbh, 6100 Darmstadt Peptide
DE3538749A1 (de) * 1985-10-31 1987-05-07 Merck Patent Gmbh Peptide
DE3626130A1 (de) * 1986-08-01 1988-02-11 Merck Patent Gmbh Aminosaeurederivate
DE3640535A1 (de) * 1986-11-27 1988-06-01 Merck Patent Gmbh Peptide
US7490044B2 (en) * 2004-06-08 2009-02-10 Bose Corporation Audio signal processing

Also Published As

Publication number Publication date
EP0444156A1 (en) 1991-09-04
EP0444156A4 (en) 1992-12-09
CA2003382A1 (en) 1990-05-21
WO1990005531A1 (en) 1990-05-31
GR890100773A (en) 1990-12-31

Similar Documents

Publication Publication Date Title
TR199900827T2 (xx) Siklooksigenaz-2 inhibit�rlerinin neoplazinin tedavisinde ve �nlenmesinde kullan�m�.
MEP27808A (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
PT1143955E (pt) Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
DE69534549D1 (de) Kombination von retroviralen proteasehennern
FR2740339B1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
HUP9800729A2 (hu) Arteriovénás és graft kezelések: módszerek és készítmények
DE69410254T2 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
DE60019321D1 (de) Verfahren zum screening von inhibitoren von asp2
GR1001145B (el) Μεθοδος για την αντιμετωπιση αγγειακων ασθενειων.
DE69611452T2 (de) Benzothiophenderivate
ES2102097T3 (es) Acidos fenilalcan(quen)oicos con actividad antagonista del leucotrieno b4.
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
ES2171419T3 (es) Uso de los inhibidores del citocromo p450 para inhibir el metabolismo del nitrogeno sustituido acridina.
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE68920757D1 (de) Lysyl-Oxidase-Inhibitoren.
DE69623325T2 (de) 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus
ATE178486T1 (de) Verwendung von kardiotonischen mitteln und inhibitoren der stickstoffoxidsynthese zur linderung von pathologisch verringertem blutdruck
DE69930844D1 (de) Inhibitoren von mycobakterien
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
ATE233570T1 (de) Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten